🚀 VC round data is live in beta, check it out!
Luzhu Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Luzhu Biotech and similar public comparables like Cormedix, Prothena Corp., TTY Biopharm, Verastem and more.
Luzhu Biotech Overview
About Luzhu Biotech
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Founded
2013
HQ
Employees
164
Website
Sectors
Financials (FY)
EV
$563M
Luzhu Biotech Financials
Luzhu Biotech reported last fiscal year revenue of — and negative EBITDA of ($21M).
In the same fiscal year, Luzhu Biotech generated ($21M) in EBITDA losses and had net loss of ($25M).
Revenue (LTM)
Luzhu Biotech P&L
In the most recent fiscal year, Luzhu Biotech reported revenue of — and EBITDA of ($21M).
Luzhu Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($21M) | XXX | XXX | XXX |
| Net Profit | ($22M) | XXX | ($25M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Luzhu Biotech Stock Performance
Luzhu Biotech has current market cap of $584M, and enterprise value of $563M.
Market Cap Evolution
Luzhu Biotech's stock price is $2.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $563M | $584M | 2.3% | XXX | XXX | XXX | $-0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLuzhu Biotech Valuation Multiples
Luzhu Biotech trades at (26.9x) EV/EBITDA.
EV / Revenue (LTM)
Luzhu Biotech Financial Valuation Multiples
As of April 18, 2026, Luzhu Biotech has market cap of $584M and EV of $563M.
Equity research analysts estimate Luzhu Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Luzhu Biotech has a P/E ratio of (26.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $584M | XXX | $584M | XXX | XXX | XXX |
| EV (current) | $563M | XXX | $563M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (26.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (20.9x) | XXX | XXX | XXX |
| P/E | (26.8x) | XXX | (23.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Luzhu Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Luzhu Biotech Margins & Growth Rates
Luzhu Biotech's revenue in the last fiscal year grew by —.
Luzhu Biotech's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Luzhu Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (39%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Luzhu Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Cormedix | XXX | XXX | XXX | XXX | XXX | XXX |
| Prothena Corp. | XXX | XXX | XXX | XXX | XXX | XXX |
| TTY Biopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Verastem | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Luzhu Biotech M&A Activity
Luzhu Biotech acquired XXX companies to date.
Last acquisition by Luzhu Biotech was on XXXXXXXX, XXXXX. Luzhu Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Luzhu Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLuzhu Biotech Investment Activity
Luzhu Biotech invested in XXX companies to date.
Luzhu Biotech made its latest investment on XXXXXXXX, XXXXX. Luzhu Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Luzhu Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Luzhu Biotech
| When was Luzhu Biotech founded? | Luzhu Biotech was founded in 2013. |
| Where is Luzhu Biotech headquartered? | Luzhu Biotech is headquartered in China. |
| How many employees does Luzhu Biotech have? | As of today, Luzhu Biotech has over 164 employees. |
| Is Luzhu Biotech publicly listed? | Yes, Luzhu Biotech is a public company listed on HKEX. |
| What is the stock symbol of Luzhu Biotech? | Luzhu Biotech trades under 02480 ticker. |
| When did Luzhu Biotech go public? | Luzhu Biotech went public in 2023. |
| Who are competitors of Luzhu Biotech? | Luzhu Biotech main competitors are Cormedix, Prothena Corp., TTY Biopharm, Verastem. |
| What is the current market cap of Luzhu Biotech? | Luzhu Biotech's current market cap is $584M. |
| Is Luzhu Biotech profitable? | No, Luzhu Biotech is not profitable. |
| What is the current net income of Luzhu Biotech? | Luzhu Biotech's last 12 months net income is ($22M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.